Mylan yesterday announced its Q4 2017 financial results, which were below analysts’ expectations. Sales were $3.24bn, instead of the expected $3.3bn, net profit reached $244.3m, that is a decline as compared to 2016 ($417m). Blockbuster EpiPen generated lower profits than expected. Sales in North America significantly declined (-17%), due to US healthcare organizations imposing weak prices for generic drugs. Mylan’s shares yesterday decreased approximately 2% (Nasdaq).